Clinical trials: Gastrointestinal Reflux
Gastroesophageal Reflux Disease
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.
- Trial name
- NCT01043185
- Testing
- AZD3355
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
GERD
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs.
- Trial name
- NCT00241540
- Testing
- Esomeprazole
- Where
- 119 sites in United States, Belgium and 4 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255151
- Testing
- Dexlansoprazole MR
- Where
- 100 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
GERD
Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)
Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)
- Trial name
- NCT03985319
- Testing
- YYD601 20mg, Nexium tab 20mg
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Symptomatic Gastroespohageal Reflux Disease
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will cause damage to the esophagus over time.
- Trial name
- NCT00149851
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 832 people
- Sponsor
- Novartis
Gastroesophageal Reflux Disease
A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after…
- Trial name
- NCT05660122
- Testing
- Fexuprazan Hydrochloride
- Where
- South Korea
- Volunteers
- 2,852 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
GERD
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive
The purpose of the study is to evaluate the pharmacokinetics, pharmacodynamics and safety of rabeprazole after single and multiple daily administration in children between the ages of 1 and 11 years, inclusive, with GERD.
- Trial name
- NCT00747695
- Testing
- Rabeprazole sodium
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastroesophageal Reflux Disease
The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity
The purpose of this study is to investigate the efficacy of lansoprazole combination with domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance kinetics, gastric emptying in patients with…
- Trial name
- NCT02958046
- Testing
- Lansoprazole/Domperidone
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Mitral Valve (MV) Regurgitation
A Prospective, Multicenter, Single-Arm Study to Support the Clinical Evidence Base for MRace as a Treatment Option for FMR Patients With Complex M-TEER Anatomies (FR)
A pilot study to evaluate the safety and performance of the MRace System to treat severe mitral regurgitation and to gather data on its performance thereby providing guidance for future clinical development.
- Trial name
- ACCESS-MR (FR) (NCT07757607)
- Testing
- Transcatheter mitral valve repair (MRace Implant and Delivery System)
- Volunteers
- 20 people
- Sponsor
- Polares Medical SA
Gastroesophageal Reflux Disease
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251745
- Testing
- Dexlansoprazole MR
- Where
- 95 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire.
- Trial name
- GerdQ-Greece (NCT00914342)
- Where
- 54 sites in Greece
- Volunteers
- 889 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease
The purpose of this study is to evaluate treatment in Gastroesophageal Reflux Disease (GERD) patients (aged 18~75) with endoscopically proven GERD treated with AGSPT201 Tablet.
- Trial name
- AGSPT (NCT01400945)
- Testing
- AGSPT201 Tab contains S-pantoprazole
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Endoscopically-Proven GERD, Reflux
Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the area under the plasma concentration-time curve (AUC) of esomeprazole after single oral doses of 5 mg, 10 mg or 20 mg esomeprazole in pediatric patients 1 to 11 years-old inclusive…
- Trial name
- NCT00687245
- Testing
- esomeprazole magnesium
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
GERD, Quality of Life
The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as…
- Trial name
- NCT00524251
- Testing
- esomeprazole
- Where
- 54 sites in Netherlands
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
Aortic Valve Disorder, Aortic Valve Insufficiency
Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000
The purpose of this observational trial is to gather further clinical data to confirm the safety and performance of the Edwards Pericardial Aortic Bioprosthesis, Model 11000 in this trial population.
- Conditions
- Aortic Valve Disorder, Aortic Valve Insufficiency, Aortic Valve Stenosis, Heart Failure
- Trial name
- NCT01651052
- Testing
- Heart Valve Surgery
- Where
- 2 sites in Poland
- Volunteers
- 133 people
- Sponsor
- Edwards Lifesciences
GERD (Gastroesophageal Reflux Disease)
A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures
Medication non-adherence is associated with greater morbidity and mortality in chronic disease, and has been estimated to increase healthcare costs by over $170 billion annually in the United States.1 Medication adherence is…
- Trial name
- NCT07712614
- Testing
- Fortiskap
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cosmos Rx, Inc
Gastroesophageal Reflux Disease (GERD)
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561090
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 99 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease (GERD) symptoms in patients who have a history of GERD symptoms and are currently taking an acid suppression…
- Trial name
- NCT01161602
- Testing
- Pumosetrag
- Where
- 5 sites in United States
- Sponsor
- Edusa Pharmaceuticals, Inc.
Gastroesophageal Reflux
Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France
The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management
- Trial name
- NCT00681837
- Where
- 25 sites in China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Maintenance Treatment)
The primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once daily for 24 weeks on maintenance of Reflux Esophagitis in patients with healed reflux esophagitis in comparison with omeprazole 10 mg…
- Trial name
- NCT00634114
- Testing
- Esomeprazole, Omeprazole
- Where
- 44 sites in Japan
- Volunteers
- 540 people
- Sponsor
- AstraZeneca